Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1909MR)

This product GTTS-WQ1909MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species synthetic construct
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1909MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4791MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT 5/9
GTTS-WQ9757MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ13348MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ9091MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMCgp100
GTTS-WQ8011MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ9016MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ15918MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ8324MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HN-66000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW